These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30903705)

  • 1. Bexarotene-induced hypothyroidism: Characteristics and therapeutic strategies.
    Makita N; Manaka K; Sato J; Mitani K; Nangaku M; Iiri T
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):195-200. PubMed ID: 30903705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bexarotene-induced central hypothyroidism assessed by TRH stimulation test in cutaneous T-cell lymphoma patients.
    Toi N; Kurajoh M; Miyaoka D; Nagata Y; Yamada S; Imanishi Y; Hayashi D; Tateishi C; Inaba M; Tsuruta D; Morita A; Emoto M
    Endocr J; 2022 Jan; 69(1):101-105. PubMed ID: 34433736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma.
    Sherman SI
    Clin Lymphoma; 2003 Mar; 3(4):249-52. PubMed ID: 12672276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism.
    Shimon I; Cohen O; Lubetsky A; Olchovsky D
    Thyroid; 2002 Sep; 12(9):823-7. PubMed ID: 12481949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central hypothyroidism associated with retinoid X receptor-selective ligands.
    Sherman SI; Gopal J; Haugen BR; Chiu AC; Whaley K; Nowlakha P; Duvic M
    N Engl J Med; 1999 Apr; 340(14):1075-9. PubMed ID: 10194237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bexarotene: A Rare Cause of Misleading Thyroid Function Tests.
    Pattan V; Schaab K; Sundaresh V
    Cureus; 2020 Nov; 12(11):e11591. PubMed ID: 33364113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones.
    Smit JW; Stokkel MP; Pereira AM; Romijn JA; Visser TJ
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2496-9. PubMed ID: 17440015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
    Assaf C; Bagot M; Dummer R; Duvic M; Gniadecki R; Knobler R; Ranki A; Schwandt P; Whittaker S
    Br J Dermatol; 2006 Aug; 155(2):261-6. PubMed ID: 16882161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine.
    Koulouri O; Auldin MA; Agarwal R; Kieffer V; Robertson C; Falconer Smith J; Levy MJ; Howlett TA
    Clin Endocrinol (Oxf); 2011 Jun; 74(6):744-9. PubMed ID: 21521256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma.
    Cayrol F; Revuelta MV; Debernardi M; Paulazo A; Phillip JM; Zamponi N; Sterle H; Díaz Flaqué MC; Magro C; Marullo R; Mulvey E; Ruan J; Cremaschi GA; Cerchietti L
    Mol Cancer Ther; 2022 Sep; 21(9):1485-1496. PubMed ID: 35793463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T-cell lymphoma.
    Morita A; Tateishi C; Muramatsu S; Kubo R; Yonezawa E; Kato H; Nishida E; Tsuruta D
    J Dermatol; 2020 May; 47(5):443-451. PubMed ID: 32189402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of bexarotene for Japanese patients with cutaneous T-cell lymphoma: The results of a phase 2 study (B-1201).
    Hamada T; Tokura Y; Sugaya M; Ohtsuka M; Tsuboi R; Nagatani T; Kiyohara E; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Saida T; Iwatsuki K
    J Dermatol; 2019 Jul; 46(7):557-563. PubMed ID: 31090237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between TRH-stimulated TSH and basal TSH measurement by a commercial immunoradiometric assay in the management of thyroid disease.
    De Rosa G; Testa A; Giacomini D; Carrozza C; Maussier ML; Valenza V; D'Errico GF
    Q J Nucl Med; 1996 Jun; 40(2):182-7. PubMed ID: 8909104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
    Väkevä L; Ranki A; Hahtola S
    Acta Derm Venereol; 2012 May; 92(3):258-63. PubMed ID: 22678563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levothyroxine Therapy Achieves Physiological FT3/FT4 Ratios at Higher than Normal TSH Levels: A Novel Justification for T3 Supplementation?
    Strich D; Chay C; Karavani G; Edri S; Gillis D
    Horm Metab Res; 2018 Nov; 50(11):827-831. PubMed ID: 30396211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
    Talpur R; Ward S; Apisarnthanarax N; Breuer-Mcham J; Duvic M
    J Am Acad Dermatol; 2002 Nov; 47(5):672-84. PubMed ID: 12399758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marked lowering of high-density lipoprotein cholesterol levels due to high dose bexarotene therapy.
    Basani S; Garg A
    J Clin Lipidol; 2015; 9(6):832-836. PubMed ID: 26687705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy.
    Fujimura T; Sato Y; Tanita K; Amagai R; Shimauchi T; Ogata D; Fukushima S; Miyashita A; Fujisawa Y; Kambayashi Y; Aiba S
    J Dermatol; 2020 Jun; 47(6):636-640. PubMed ID: 32207181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of abnormal thyrotropin concentrations measured by a sensitive assay in patients with type 2 diabetes mellitus.
    Celani MF; Bonati ME; Stucci N
    Diabetes Res; 1994; 27(1):15-25. PubMed ID: 7648793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas.
    Hamada T; Sugaya M; Tokura Y; Ohtsuka M; Tsuboi R; Nagatani T; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Yoshida T; Saida T; Iwatsuki K
    J Dermatol; 2017 Feb; 44(2):135-142. PubMed ID: 27543197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.